ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
58 announcements with these filters
Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.
Dr Reddy's KMP Erez Israeli sold 460,276 ADRs to cover the exercise of 591,270 ADRs allotted under ESOP. The disposal is valued at about ₹61.76 Crore.
Dr. Reddy's allotted 5,91,270 equity shares to employees on exercise of stock options under its ADR ESOP Scheme 2007. Exercise prices ranged from Re.1 to Rs.1,060.20 per share.
Dr. Reddy's confirms FDA tentative approval for its lenacapavir HIV shot. The company states the news is not material and has no material impact.
Dr Reddy's says USFDA closed its PAI and GMP inspection at Srikakulam FTO-SEZ Process Unit-02 with VAI classification. The outcome is closed with no monetary penalty.
Revenue declined 1.5% YoY as lower Revlimid sales in North America offset strong double-digit growth in base business and emerging markets.
Dr Reddy's appointed Akhil Ravi as Head API and Services and Senior Management Personnel, effective 13 November 2026. Ravi is the son-in-law of co-chairman G V Prasad.
Q2FY27 revenue ₹8,671 Cr (-1.5% YoY), EBITDA ₹1,783 Cr (20.6%), PAT ₹925 Cr (-36% YoY). Management stresses double-digit base-business growth excluding lenalidomide in North America.
Dr. Reddy's Laboratories Ltd reported revenue from operations of ₹8,698 Cr (-1.5% YoY) and net profit of ₹913.2 Cr (-31.7% YoY) for Q2 FY27.
Dr. Reddy's Laboratories Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, including notes on significant beneficial ownership.
Dr. Reddy's received DCGI approval for Zytorvi in advanced esophageal cancer, its second Indian indication. This expands first-line immunotherapy access in its oncology portfolio.
Dr. Reddy's Laboratories received a USFDA Form 483 with two observations following a Pre-Approval Inspection at its Pydibhimavaram facility. The company plans to address these observations within the stipulated timeline.
Dr. Reddy's Laboratories reported a penalty of $32,350.20 levied by the US IRS on its subsidiary due to a tax classification error. The company sees no material impact.
Dr. Reddy’s Laboratories will hold a board meeting on October 23, 2026, to approve the standalone and consolidated financial results for the quarter ending September 30, 2026.
Dr. Reddy's signed an exclusive distribution agreement with Takeda for Qdenga dengue vaccine in India's private market. No upfront consideration stated; availability expected H1 2027.
Dr. Reddy's confirmed a news report regarding a voluntary licensing agreement with Gilead Sciences for an HIV prevention drug, noting it is not material.
Dr. Reddy's Laboratories received two observations from the USFDA following a records assessment of its API manufacturing facility in Jiutepec, Mexico.
Dr. Reddy's Laboratories allotted 375 equity shares to employees upon the exercise of stock options under its ESOP scheme.
Dr. Reddy's Laboratories allotted 4,110 equity shares to employees under its 2002 Employee Stock Option Scheme. The shares rank pari passu with existing equity.
ICICI Prudential Mutual Fund acquired 7,12,884 shares of Dr. Reddy's Laboratories via the open market. This transaction increased the fund's total stake to 5.037%.
Dr. Reddy's Laboratories announced the resignation of Deepak Sapra, CEO of API and Services, effective November 12, 2026.
Dr. Reddy's Laboratories has terminated its distribution and promotion agreement with Novartis India Limited following a change in NIL's controlling shareholding.
Dr. Reddy's Laboratories received a Form 483 with three observations following a USFDA inspection at its Srikakulam FTO-SEZ unit, which the company will address.
Dr. Reddy's clarified a news report regarding Thailand's approval of its antibiotic NULZOLVENCE. The company confirmed the reports are correct and based on a joint press release.
Q1FY27 revenue fell 5.6% YoY to ₹8,071 Cr due to lower Lenalidomide sales. EBITDA margin at 12.5% (15.4% ex-one-offs) was hit by semaglutide API issues and Middle East conflict costs.
Dr. Reddy's Laboratories concluded its 42nd Annual General Meeting on July 23, 2026, with shareholders approving all agenda items, including a final dividend of ₹8 per share.
Q1FY27 revenues reached ₹8,071 Cr with 12.5% EBITDA margin. Results were significantly impacted by a ₹240 Cr semaglutide API charge; underlying EBITDA margin before this impact was 15.4%.
Dr. Reddy's Laboratories granted 15,933 stock options under its 2018 employee stock option scheme. The grant follows approval from the company's compensation committee.
Dr. Reddy's Laboratories appointed Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel, and appointed Deloitte Haskins & Sells, LLP for US reporting.
Dr. Reddy's Laboratories Ltd reported revenue from operations of ₹8,100 Cr (-5.5% YoY) and net profit of ₹435.6 Cr (-69.1% YoY) for Q1 FY27.